{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027267","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.619580+00:00","generated_at":"2026-06-21T19:49:55.525676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AcelRx reports Q3 net loss of $6.9M, DSUVIA sales up 217% YoY to $0.5M","bullets":["DSUVIA net sales $0.5M in Q3 2022, up 217% vs Q3 2021; units sold 1,032 vs 371.","Net loss $6.9M ($0.94 per share) vs $8.4M ($1.40) in Q3 2021; cash $20.9M.","Combined R&D and SG&A expenses fell to $6.6M from $10.1M on cost reductions.","Niyad development batch produced; potential EUA submission targeted for H1 2023.","Ephedrine pre-filled syringe NDA submission expected by year-end; DSUVIA strategic partner by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027267","json":"https://secwatch.observer/filing/0001437749-22-027267.json","markdown":"https://secwatch.observer/filing/0001437749-22-027267.md","text":"https://secwatch.observer/filing/0001437749-22-027267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922027267/0001437749-22-027267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922027267/acrx20221111_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:49:55.525676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54acf9eac0b9cf3a872caf8d4d3724386c7d4fc4","claim":"TALPHERA, INC. reported the third quarter of 2022 results: revenue $0.5 million, net income $6.9 million, EPS $0.94 per basic and diluted share.","evidence_excerpt":"● Third quarter 2022 DSUVIA net sales were $0.5 million, a 217% increase over 2021; year-to-date September 30, 2022 DSUVIA net sales were $1.5 million, representing a 51% increase over the same period in 2021. Total DSUVIA units sold in the third quarter of 2022 were 1,032 compared to 371 units in 2021. Total net revenues in the third quarter 2022 of $0.5 million declined $1.4 million compared to the same period in 2021 due to the recognition of $1.7 million in revenues in the third quarter of 2021 attributed to an upfront payment received related to our DZUVEO European licensing agreement. ● Combined R&D and SG&A expenses for the third quarter of 2022 totaled $6.6 million compared to $10.1 million for the third quarter of 2021. Excluding non-cash depreciation and stock-based compensation expense, these amounts were $5.7 million for the third quarter of 2022, compared to $8.6 million for the third quarter of 2021. The decrease in combined R&D and SG&A expenses in the third quarter of 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922027267/0001437749-22-027267-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"$6.9 million"},{"label":"EPS","value":"$0.94 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}